Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State

Inclusion Criteria: * Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions; * Able to complete the study according to the requirements of the trial protocol; * The participants (including their partners) are willing to voluntarily use effective contraceptive methods within 6 months from screening until the last dose of study drug, as detailed in the Appendix; * Male and female subjects aged 18-55 years old (including 18 and 55 years old); * he body weight of male subjects should not be less than 50 kg and the body weight of female subjects should not be less than 45 kg. Body mass index (BMI) = weight (kg)/height 2 (m2), BMI in the range of 18-28 kg/m2 (including the cut-off value); * Health condition: History of no heart, liver, kidney, digestive tract, nervous system, mental disorders, metabolic disorders, etc； * The physical examination was normal or abnormal without clinical significance. Exclusion Criteria: * Smoking more than 5 cigarettes per day in the 3 months before the study; * Allergic constitution (multi-drug and food allergy); * A history of drug and/or alcohol abuse (drinking 14 units of alcohol per week: 1 unit = 285 mL beer, or 25 mL spirits, or 100 ml wine); * Donation or massive blood loss (\> 400 mL) within 3 months before screening; * Taking any drugs that alter liver enzyme activity 28 days before screening; * Have taken any prescription medication, over-the-counter medication, any vitamin product or herbal medicine within 14 days before screening; * Those who had taken special diet (including dragon fruit, mango, grapefruit, etc.) or had strenuous exercise within 2 weeks before screening, or had other factors affecting drug absorption, distribution, metabolism, and excretion; * Combined with the following inhibitors or inducers of CYP3A4, P-gp, or Bcrp, such as itraconazole, ketoconazole, or dronedarone; * A recent major change in diet or exercise habits; * Have taken a study drug or participated in a clinical trial of the drug within three months before taking the study drug; * A history of dysphagia or any gastrointestinal disorder affecting drug absorption or a history of cholecystectomy or biliary tract disease; * Have any condition that increases the risk of bleeding, such as hemorrhoids, acute gastritis or gastric and duodenal ulcers; * ECG abnormalities have clinical significance; * The female subjects were lactating or seropositive for pregnancy during the screening or test period; * Clinically significant abnormalities on clinical examination or other clinical findings (including but not limited to gastrointestinal, renal, hepatic, neurological, hematologic, endocrine, oncologic, pulmonary, immune, psychiatric, or cardio-cerebrovascular diseases); * Viral hepatitis (including hepatitis B and C), AIDS antibody, treponema pallidum antibody positive; * From the screening stage to the onset of acute illness before study medication; * Consumption of chocolate, any caffeinated or xanthine-rich food or beverage 48 hours before taking the study drug; * Have taken any alcohol-based product within 24 hours before taking the study medication; * Individuals who test positive for alcohol and drugs or have a history of drug abuse within the past five years or have used drugs in the three months prior to the experiment; * Difficulty in blood collection or inability to tolerate venipuncture blood collection; * The subject is unable or unable to comply with ward management regulations; * The subject is unable to complete the experiment due to personal reasons; * Other researchers determine that it is not suitable for selection in this project.